There are 2949 resources available
1008P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masafumi Ikeda
Session: E-Poster Display
Resources:
Abstract
1009P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: E-Poster Display
Resources:
Abstract
1011P - The experience associated with caregiving for patients with intermediate stage hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolisation (TACE) treatment
Presenter: Julien Edeline
Session: E-Poster Display
Resources:
Abstract
1010P - Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE study
Presenter: Philippe Merle
Session: E-Poster Display
Resources:
Abstract
1012P - Analysis of tumor location related oncologic characteristics of hepatocellular carcinoma
Presenter: Wei Fan
Session: E-Poster Display
Resources:
Abstract
1013P - PTPN13 inactivation by hepatitis B virus X regulates metabolic reprogramming for hepatocellular carcinoma progression
Presenter: Yongcong Yan
Session: E-Poster Display
Resources:
Abstract
1014TiP - PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
Presenter: Ghassan Abou-Alfa
Session: E-Poster Display
Resources:
Abstract
1015TiP - Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
Presenter: Richard Finn
Session: E-Poster Display
Resources:
Abstract
1016TiP - LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Presenter: Josep Llovet
Session: E-Poster Display
Resources:
Abstract
1017TiP - KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
Presenter: Arndt Vogel
Session: E-Poster Display
Resources:
Abstract